Drugs / LY4005130
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06690996 | Nov 2024 → Apr 2026 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07533006 | Apr 2026 → Jun 2027 expected | alopecia areata | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 2 | NCT07533019 | Apr 2026 → May 2027 expected | vitiligo | Eli Lilly and Company | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY4005130 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07533006 ↗ |
| Route | Intravenous | “Administered IV” NCT06690996 ↗ |